News & Updates
Filter by Specialty:
C3 levels tied to incident T2DM; BMI plays a mediating role
Complement C3 levels may be used as a predictor of incident type 2 diabetes mellitus (T2DM), suggests a study. In addition, body mass index (BMI) may have a mediating role in the association between C3 and T2DM, offering clues for diabetes pathogenesis.
C3 levels tied to incident T2DM; BMI plays a mediating role
16 Mar 2023
Cyclophosphamide-free adjuvant chemo works against ERBB2-negative breast cancer
The adjuvant chemotherapy regimen epirubicin plus paclitaxel (EP) appears to be as good as the regimen that consists of epirubicin and cyclophosphamide followed by paclitaxel (EC-P) in the treatment of Asian women with operable ERBB2-negative breast cancer, according to the results of an open-label phase III trial.
Cyclophosphamide-free adjuvant chemo works against ERBB2-negative breast cancer
15 Mar 2023
Pituitary-targeting seliciclib shows promise in treatment of Cushing disease
In a recent study, seliciclib therapy demonstrates its potential in reversing hypercortisolism by directly targeting pituitary corticotrophs in Cushing disease (CD). However, the agent is associated with liver toxicity, which is resolved by withdrawing treatment.
Pituitary-targeting seliciclib shows promise in treatment of Cushing disease
15 Mar 2023
TKI therapy may improve survival in metastatic pheochromocytomas/paragangliomas
Treatment with tyrosine kinase inhibitors (TKIs), such as sunitinib, provides survival benefits to patients with metastatic pheochromocytomas/paragangliomas (PPGLs), suggests a recent study.
TKI therapy may improve survival in metastatic pheochromocytomas/paragangliomas
15 Mar 2023
Add-on evolocumab improves plaque characteristics in statin-treated CAD patients
In individuals with stable coronary artery disease (CAD), intensifying their lipid-lowering regimen with evolocumab, a PCSK9* inhibitor, led to improvements in coronary plaque characteristics on intravascular imaging, findings from the YELLOW III trial have shown.